Full video transcriptClick to expand
Auto-generated transcript of @gilletthealth's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00What is the number one mistake that guys make on TRT?
- 0:06The number one mistake guys make on TRT
- 0:08is not following up on health metrics
- 0:12that can be affected by that testosterone
- 0:14in a positive way or a negative way.
- 0:16They're not following up on body composition,
- 0:19red blood cell count, blood pressure,
- 0:22their levels of testosterone.
- 0:23Many of these things could be measured
- 0:25and the dose of testosterone perhaps adjusted
- 0:28to get them the best outcomes with the little downside.
The number one TRT mistake: what the science actually says
Quick answer
TRT monitoring is a regulatory and clinical requirement, not just a best practice. The Endocrine Society's 2018 clinical practice guideline specifies hematocrit, PSA, and serum testosterone checks at defined intervals, with additional cardiovascular and metabolic markers recommended based on individual patient risk. The creator's advice aligns with standard monitoring frameworks but omits estradiol, which is a relevant gap for men experiencing side effects related to aromatization.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For The number one TRT mistake: what the science actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
The number one TRT mistake: what the science actually says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "The number one TRT mistake: what the science actually says" from Gillett Health. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: TRT monitoring is a regulatory and clinical requirement, not just a best practice.
The reason this review is not generic is the source wording and the canonical claim label "trt number 1 mistake guys make on trt testosterone trt hormones." In this clip, the useful excerpt is: "What is the number one mistake that guys make on TRT?" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
TRT monitoring is a regulatory and clinical requirement, not just a best practice.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- TRT monitoring is a regulatory and clinical requirement, not just a best practice. The Endocrine Society's 2018 clinical practice guideline specifies hematocrit, PSA, and serum testosterone checks at defined intervals, with additional cardiovascular and metabolic markers recommended based on individual patient risk. The creator's advice aligns with standard monitoring frameworks but omits estradiol, which is a relevant gap for men experiencing side effects related to aromatization.
- The Endocrine Society recommends hematocrit, PSA, and serum testosterone checks at 3 months, 6 months, and annually during TRT, making monitoring a clinical standard, not optional.
- A hematocrit above 54% is the standard threshold that should prompt dose reduction or therapy pause, according to the 2018 Endocrine Society guidelines.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The Endocrine Society recommends hematocrit, PSA, and serum testosterone checks at 3 months, 6 months, and annually during TRT, making monitoring a clinical standard, not optional.
- A hematocrit above 54% is the standard threshold that should prompt dose reduction or therapy pause, according to the 2018 Endocrine Society guidelines.
- The TRAVERSE trial (Lincoff et al., 2023, NEJM) found higher atrial fibrillation rates in testosterone-treated men, reinforcing the case for ongoing cardiovascular monitoring.
- Estradiol was not mentioned in this video but should be on any TRT monitoring list, since testosterone aromatizes to estrogen and elevated estradiol affects mood, libido, and bone metabolism.
- Body composition changes on TRT are real and dose-dependent per Bhasin et al. (2001, NEJM), but magnitude varies enough that individual tracking is more informative than population averages.
- Polycythemia, not a modest RBC increase, is the clinically significant hematologic risk on TRT. The distinction between RBC count and hematocrit matters for patient understanding.
- Patients starting TRT through any channel, telehealth or in-person, should expect baseline labs, follow-up labs at 3 to 6 months, and periodic checks thereafter as part of standard care.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @gilletthealth actually say?
The claim is straightforward: the biggest mistake men make on TRT is skipping follow-up monitoring. Specifically, the creator flagged body composition, red blood cell count, blood pressure, and testosterone levels as things that should be tracked and used to adjust dosing. That is a narrow, clinical argument, not a lifestyle pitch.
To be precise, the creator said men should be following up on "health metrics that can be affected by that testosterone in a positive or negative way." The framing is appropriately cautious. They are not promising outcomes, just arguing that you cannot optimize what you are not measuring. That is a defensible starting point.
Does the science back this up?
Yes, substantially. The evidence for routine monitoring during TRT is not controversial, and the specific markers named here are the right ones to watch. Hematocrit elevation is one of the most documented dose-dependent adverse effects of testosterone therapy. A 2010 meta-analysis by Calof et al. in the Journals of Gerontology found hematocrit increases were significantly more common in testosterone-treated men than controls, with polycythemia rates climbing with higher doses.
Blood pressure is trickier. The relationship between exogenous testosterone and cardiovascular risk is still being untangled. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), which enrolled over 5,000 hypogonadal men, found non-inferiority on major cardiac events, but also a higher rate of atrial fibrillation in the testosterone group. That is not nothing. Monitoring blood pressure and cardiac markers matters, and the creator is right to name it.
Body composition changes on TRT, specifically lean mass gains and fat mass reduction, are well-documented (Bhasin et al., 2001, NEJM), though magnitude varies significantly by baseline status, age, and dose.
What did they get wrong, or right?
Mostly right, with one gap worth naming. The creator listed red blood cell count, which is good but incomplete. Clinicians tracking hematocrit on TRT are really watching for erythrocytosis, not just a generic RBC bump. The threshold that typically prompts intervention is a hematocrit above 54%, per Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). Saying "red blood cell count" without that context could leave someone thinking a mildly elevated RBC is the thing to worry about, when the real risk is hyperviscosity from elevated hematocrit.
Also absent from the list: estradiol. Testosterone aromatizes to estrogen, and estradiol levels affect everything from libido to bone density to mood. Most clinicians treating hypogonadism check it routinely. Leaving it off a monitoring checklist is a real omission, not a technicality.
That said, the overall message, get labs, see a clinician, adjust based on data, is sound. This video is not selling anything dangerous.
What should you actually know?
If you are on TRT through any legitimate channel, including a regulated telehealth platform, you should expect to get blood work done before starting, at follow-up intervals during dose adjustment, and periodically once stable. This is not optional and it is not upselling. It is how the therapy is supposed to work.
The Endocrine Society recommends checking hematocrit, PSA (in men over 40), and testosterone levels at 3 and 6 months after initiating therapy, then annually. Blood pressure should be tracked at every clinical contact. Some clinicians also check a lipid panel and liver enzymes depending on individual risk factors.
The creator's framing, that skipping these checks is the "number one mistake," is probably accurate from a population-health standpoint. Most serious adverse events tied to TRT, including polycythemia, blood clots, and cardiovascular events, are more manageable when caught early through routine monitoring rather than after symptoms appear.
- Hematocrit above 54% is the standard threshold for pausing or reducing testosterone dose.
- Estradiol monitoring is not optional for many patients and was conspicuously missing from this video's list.
- Blood pressure monitoring matters, especially given the TRAVERSE trial's atrial fibrillation finding.
- Testosterone level targets vary by formulation and individual, which is why periodic measurement matters for dose adjustment.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Gillett Health · TikTok creator
7.4K views on this video
Number 1 mistake guys make on TRT #testosterone #trt #hormones #menshealth
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the endocrine society recommends hematocrit, psa,?
The Endocrine Society recommends hematocrit, PSA, and serum testosterone checks at 3 months, 6 months, and annually during TRT, making monitoring a clinical standard, not optional.
What does the video say about a hematocrit above 54%?
A hematocrit above 54% is the standard threshold that should prompt dose reduction or therapy pause, according to the 2018 Endocrine Society guidelines.
What does the video say about the traverse trial (lincoff et al., 2023, nejm) found higher?
The TRAVERSE trial (Lincoff et al., 2023, NEJM) found higher atrial fibrillation rates in testosterone-treated men, reinforcing the case for ongoing cardiovascular monitoring.
What does the video say about estradiol was not mentioned in this video?
Estradiol was not mentioned in this video but should be on any TRT monitoring list, since testosterone aromatizes to estrogen and elevated estradiol affects mood, libido, and bone metabolism.
What does the video say about body composition changes on trt?
Body composition changes on TRT are real and dose-dependent per Bhasin et al. (2001, NEJM), but magnitude varies enough that individual tracking is more informative than population averages.
What does the video say about polycythemia, not a modest rbc increase,?
Polycythemia, not a modest RBC increase, is the clinically significant hematologic risk on TRT. The distinction between RBC count and hematocrit matters for patient understanding.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Gillett Health, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.